Their primary goal was to provide pain-management practitioners, referrers, primary care providers, and purchasers of health care with clear, primarily evidence-based guidelines and consensus ...

PHI is usually defined as chronic neuropathic ... NRS pain score. 3. Rash characteristics: Type of lesion (blistering erythema or papule), location of lesion (head and face; chest and back; waist and ...

The terrible pain started a week earlier, and she had already been to the emergency room twice. By Lisa Sanders, M.D. “You need to go back to the hospital,” the visiting nurse declared shortly ...

“Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body ...

Eisenberg’s remarkable film—which won Eisenberg the Waldo Salt Screenwriting Award at Sundance earlier this year—is like that mislaid second marker: heartfelt, awkward, full of pain it’s ...

Boston biotech Ax­o­nis Ther­a­peu­tics has raised a $115 mil­lion Se­ries A to test whether its oral drug AXN-027 can help pa­tients with fo­cal epilep­sy and … ...

CEO and cofounder Joanna Stanicka calls this a huge milestone and says the money will help fund a Phase 1 clinical trial of the firm’s neuropathic pain treatment that is scheduled to begin at ...

and Vertex Pharmaceuticals is on the verge of gaining an FDA approval for suzetrigine (VX-548), a nonaddictive oral treatment that is on track to become the first major shift in pain treatment for ...

Jill Becher woke up one fall morning with what felt like a bad sore throat. For a few days, she pushed the pain aside. But when it didn't fade, she went to urgent care. Doctors there found no ...

More information: Carlos Raul Ramirez Medina et al, Clinical indications associated with new opioid use for pain management in the United Kingdom: using national primary care data, Pain (2024 ...

Finnish pharma group Orion (HEL: ORNBV) has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for ...